Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

GERN - Geron Corporation So'nggi Yangiliklar | Finranks

Home

GERN

G

Geron Corporation (GERN)

NMS – Real vaqt narxi. Valyuta: USD

1.40

-0.14 (-9.09%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.41

+0.01 (0.71%)

Bozordan keyin: Mar 27, 2026, 7:57 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Geron Announces Appointment of New Members to its Board of Directors

Geron Announces Appointment of New Members to its Board of Directors

Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies

Geron: Minimal Sales Growth But A Potential Run-Up Ahead

Geron: Minimal Sales Growth But A Potential Run-Up Ahead

Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings

Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings

Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European pricing negotiations suggest a more cautious outlook for RYTELO's global commercial expansion.

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

Geron Corporation (GERN) Q4 2025 Earnings Call Transcript

Geron Corporation (GERN) Q4 2025 Earnings Call Transcript

Geron Corporation (GERN) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Geron Announces Appointment of New Members to its Board of Directors

Geron Announces Appointment of New Members to its Board of Directors

Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to purchase an aggregate of 742,500 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron.